Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer

Abstract

Background: Treatment of early-stage non-small cell lung cancer (NSCLC) is rapidly evolving. When introducing novelties, real-life data on effectiveness of currently used treatment strategies are needed. This study evaluated outcomes of stage I-IIIA NSCLC patients treated with upfront radical surgery in everyday clinical practice, between 2010-2017.

Materials and Methods: Data of 539 consecutive patients were retrieved from a prospective hospital-based registry. All diagnostic, treatment and follow-up procedures were performed at the same thoracic oncology centre according to the valid guidelines. The primary outcome was overall survival (OS) analysed by clinical(c) and pathological(p) TNM (tumour, node, metastases) stage. The impact of clinicopathological characteristics on OS was evaluated using univariable (UVA) and multivariable regression analysis (MVA).

Results: With a median follow-up of 53,9 months, median OS and 5-year OS rate in the overall population were 90,4 months and 64,4%. Five-year OS rates by pTNM stage I, II and IIIA were 70,2%, 60,21%, and 49,9 %, respectively. Both cTNM and pTNM stages were associated with OS; but only pTNM retained its independent prognostic value (p=0,003) in MVA. Agreement between cTNM and pTNM was 69,0%. Next to pTNM, age (p=0,001) and gender (p=0,004) retained their independent prognostic value for OS.

Conclusions: Our study showed favourable outcomes of resectable stage I-IIIA NSCLC treated with upfront surgery in real-life. Relatively low agreement between cTNM and pTNM stages and independent prognostic value of only pTNM, observed in real-life data, suggest that surgery remains the most accurate provider of the anatomical stage of disease and important upfront therapy.